169 related articles for article (PubMed ID: 26456240)
1. Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors.
Sarkar S; Cohen N; Sabhachandani P; Konry T
Lab Chip; 2015 Dec; 15(23):4441-50. PubMed ID: 26456240
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
4. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
5. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
6. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
7. [Effect of cyclosporin A on intracellular accumulation and efflux of drug in K562/DOX cells].
Meng H; Lin X; Lin M
Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):254-6. PubMed ID: 15622758
[TBL] [Abstract][Full Text] [Related]
8. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
10. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
11. Gold nanorod-cored biodegradable micelles as a robust and remotely controllable doxorubicin release system for potent inhibition of drug-sensitive and -resistant cancer cells.
Zhong Y; Wang C; Cheng L; Meng F; Zhong Z; Liu Z
Biomacromolecules; 2013 Jul; 14(7):2411-9. PubMed ID: 23701318
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
14. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
15. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
17. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
[TBL] [Abstract][Full Text] [Related]
18. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
19. Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.
Zhao Y; Chen F; Pan Y; Li Z; Xue X; Okeke CI; Wang Y; Li C; Peng L; Wang PC; Ma X; Liang XJ
ACS Appl Mater Interfaces; 2015 Sep; 7(34):19295-305. PubMed ID: 26270258
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
